Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind crossover study of psilocybin microdosing with psychotherapy in treatment-resistant depression
MOH_2025-06-24_012057Phase 2Not yet recruiting
- Sponsor
- דר עודד ארבל
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin in treatment-resistant depression (TRD) and major depressive disorder (MDD) (2 arms), sponsored by דר עודד ארבל. Primary endpoint: Clinical depression symptom measures. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on MOH_2025-06-24_012057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-06-24_012057.